Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lexy S. Wadsworth"'
Autor:
Charlotte R. Feddersen, Lexy S. Wadsworth, Eliot Y. Zhu, Hayley R. Vaughn, Andrew P. Voigt, Jesse D. Riordan, Adam J. Dupuy
Publikováno v:
BMC Genomics, Vol 20, Iss 1, Pp 1-12 (2019)
Abstract Background The introduction of genome-wide shRNA and CRISPR libraries has facilitated cell-based screens to identify loss-of-function mutations associated with a phenotype of interest. Approaches to perform analogous gain-of-function screens
Externí odkaz:
https://doaj.org/article/deb2d1614bf845a88c127a675c0779c0
Autor:
Adam J. Dupuy, Christopher S. Stipp, Jesse D. Riordan, Jeremy Bobera, Sarah A. Mullen, Brooke M. Jennings, Eliot Y. Zhu, Andrew P. Voigt, Lexy S. Wadsworth, Hayley R. Vaughn, Afshin Varzavand, Jacob L. Schillo, Charlotte R. Feddersen
The use of selective BRAF inhibitors (BRAFi) has produced remarkable outcomes for patients with advanced cutaneous melanoma harboring a BRAFV600E mutation. Unfortunately, the majority of patients eventually develop drug-resistant disease. We employed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eaeb0dd15610b75d4835c5c2b200b47
https://doi.org/10.1158/0008-5472.c.6510806
https://doi.org/10.1158/0008-5472.c.6510806
Autor:
Adam J. Dupuy, Christopher S. Stipp, Jesse D. Riordan, Jeremy Bobera, Sarah A. Mullen, Brooke M. Jennings, Eliot Y. Zhu, Andrew P. Voigt, Lexy S. Wadsworth, Hayley R. Vaughn, Afshin Varzavand, Jacob L. Schillo, Charlotte R. Feddersen
Supplemental figures showing more detailed analysis of the genetic screen results (S1-S3), additional experiments showing biological validation of major candidate genes (S4-S7), and characterization of spontaneous Vemurafenib resistance in A375 cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::763c2810c62639764eae9b5898ddc732
https://doi.org/10.1158/0008-5472.22420994
https://doi.org/10.1158/0008-5472.22420994
Autor:
Adam J. Dupuy, Christopher S. Stipp, Jesse D. Riordan, Jeremy Bobera, Sarah A. Mullen, Brooke M. Jennings, Eliot Y. Zhu, Andrew P. Voigt, Lexy S. Wadsworth, Hayley R. Vaughn, Afshin Varzavand, Jacob L. Schillo, Charlotte R. Feddersen
This file contains 4 supplemental tables.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bb40e1219583d6c2b577a68cb4a9de0
https://doi.org/10.1158/0008-5472.22420997.v1
https://doi.org/10.1158/0008-5472.22420997.v1
Autor:
Jeremy Bobera, Charlotte R. Feddersen, Sarah A. Mullen, Jesse D. Riordan, Lexy S. Wadsworth, Jacob L. Schillo, Adam J. Dupuy, Hayley R. Vaughn, Christopher S. Stipp, Brooke M. Jennings, Andrew P. Voigt, Afshin Varzavand, Eliot Y. Zhu
Publikováno v:
Cancer Research. 79:5074-5087
The use of selective BRAF inhibitors (BRAFi) has produced remarkable outcomes for patients with advanced cutaneous melanoma harboring a BRAFV600E mutation. Unfortunately, the majority of patients eventually develop drug-resistant disease. We employed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6f4adc244e6e093a02c0e524ce30cb6
https://doi.org/10.1158/0008-5472.can-19-0244
https://doi.org/10.1158/0008-5472.can-19-0244
Autor:
Eliot Y. Zhu, Christopher S. Stipp, Lexy S. Wadsworth, Afshin Varzavand, Adam J. Dupuy, Hayley R. Vaughn, Charlotte R. Feddersen, Jacob L. Schillo, Andrew P. Voigt, Jesse D. Riordan
Publikováno v:
Cancer Research. 80:B08-B08
The serine/threonine protein kinase BRAF is mutated in approximately 50% of cutaneous melanomas, leading to hyperactivation of the MAPK/ERK pathway. The most common mutations, BRAFV600, can be targeted by selective kinase inhibitors, such as vemurafe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26f96739d9f666291119367ed3ada86d
https://doi.org/10.1158/1538-7445.mel2019-b08
https://doi.org/10.1158/1538-7445.mel2019-b08
Autor:
Adam J. Dupuy, Hayley R. Vaughn, Charlotte R. Feddersen, Andrew P. Voigt, Lexy S. Wadsworth, Jacob L. Schillo, Christopher S. Stipp, Eliot Y. Zhu
Publikováno v:
Cancer Research. 78:LB-096
Melanoma is the deadliest form of skin cancer, and until recently patients had few treatment options upon diagnosis. Fortunately, this lack of treatment options changed with the discovery of vemurafenib, a highly selective kinase inhibitor that speci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14604dc389b1133fdd723dc7fac153a6
https://doi.org/10.1158/1538-7445.am2018-lb-096
https://doi.org/10.1158/1538-7445.am2018-lb-096